Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-08

Clinical Trial Update: Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

This document reports an active Phase 2 placebo-controlled trial evaluating ESK-001 for active systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ESK-001

Snippet

Sponsor: Alumis Inc | Conditions: SLE | Phase 2 | Status: ACTIVE_NOT_RECRUITING